Treatment of recurrent aphthous stomatitis with oral roflumilast, a multicenter observational study
This study suggests that roflumilast may effectively treat RAS by reducing the number of flare-ups and ulcers, their duration, and the symptomatology produced by the ulcers. In addition, roflumilast has a good safety profile, is well tolerated at low doses, and does not require close monitoring. These characteristics and its favorable economic profile make roflumilast a promising therapeutic option in this pathology.
Authors
- Carolina Labrandero Hoyos (ORCID: https://orcid.org/0000-0002-3270-7428)
- Leticia Bagán (ORCID: https://orcid.org/0000-0002-4499-1999)
- Ángel González García (ORCID: https://orcid.org/0009-0001-5071-9369)
- Rodrigo Peñuelas Leal (ORCID: https://orcid.org/0000-0002-9627-780X)
- José Vicente Bagán Sebastián (ORCID: https://orcid.org/0000-0002-0295-2916)
- Malena Finello (ORCID: https://orcid.org/0000-0003-0711-3481)
- Andrés Grau Echevarría (ORCID: https://orcid.org/0000-0003-2557-3107)
- Sandra Martínez‐Fernández (ORCID: https://orcid.org/0000-0003-4534-7828)
- Daniel Blaya Imbernón (ORCID: https://orcid.org/0009-0002-7667-600X)
- Elena Pérez Zafrilla
- Violeta Zaragozá Ninet
- Jose Amancio Peñuelas Ruiz
- Gemma Pérez Pastor
- José Luís Sánchez Carazo
- Miguel Martí Cabrera
Institutions
- Universitat de València (ES)
- Hospital General Universitario De Valencia (ES)
- Complejo Hospitalario de Pontevedra (ES)
Publication Details
- Journal
- International Journal of Dermatology
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1111/ijd.17478
- Citations
- 5
- Primary Topic
- Medicinal plant effects and applications
- Type
- article
- Field-Weighted Citation Impact
- 3.58